UnknownPhase 2NCT01595061
Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva
Studying Vulvar carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gynecologic Oncology Group
- Principal Investigator
- Neil S Horowitz, MDNRG Oncology
- Intervention
- Cisplatin(drug)
- Enrollment
- 57 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2012 – 2022
Study locations (30)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
- Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
- Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
- Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
- Alaska Women's Cancer Care, Anchorage, Alaska, United States
- Anchorage Oncology Centre, Anchorage, Alaska, United States
- Katmai Oncology Group, Anchorage, Alaska, United States
- Providence Alaska Medical Center, Anchorage, Alaska, United States
- Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
- Hartford Hospital, Hartford, Connecticut, United States
- The Hospital of Central Connecticut, New Britain, Connecticut, United States
- Beebe Medical Center, Lewes, Delaware, United States
- Christiana Gynecologic Oncology LLC, Newark, Delaware, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01595061 on ClinicalTrials.govOther trials for Vulvar carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06447064Cancer Loyalty Card Study 2 (CLOCS-2)Imperial College London
- RECRUITINGNCT07380698The Effect of Dose and Storage Conditions of Indocyanine Green on Efficacy and Cost in Sentinel Lymph Node Mapping in Gynecological CancerCukurova University
- ENROLLING BY INVITATIONNANCT07023601International Prospective Multicentre Study That Evaluate the Sentinel Lymph Node Detection Rate in Patients With First Local Recurrent Scamous Cell Carcinoma of the Vulva.Hospital Universitario La Paz
- RECRUITINGPHASE2NCT05903833Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or RadiotherapyAGO Research GmbH
- RECRUITINGNANCT05576831STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide ExcisionBritish Columbia Cancer Agency
- RECRUITINGNANCT06495554Danish Vulva Cancer Recurrence StudyUniversity of Aarhus
- RECRUITINGNANCT06264167NODE (groiN ultrasOunD cancEr)Queensland Centre for Gynaecological Cancer
- ACTIVE NOT RECRUITINGNANCT06694116Charcoal Carbon Black Dye Use in Sentinel Lymph Node Mapping in Early Stage Vulvar CancerIstanbul University